Newswire (Published: Monday, April 20, 2020, 10:16:00 PM CDT, Received: Tuesday, April 21, 2020, 7:00:32 PM CDT)
Word Count: 318
In a phase III, randomized controlled trial (RTOG 96-01), Decipher Prostate RP from Decipher Biosciences,
Hormone therapy is often administered in combination with radiotherapy as a treatment for men with localized prostate cancer who experience disease recurrence following surgical removal of their prostate. To determine the efficacy of hormonal therapy in this setting, the RTOG 96-01 trial investigated treatment of patients with radiotherapy alone versus combined radiation and hormonal therapy, with a 12-year follow-up.
Upon completion of RTOG 96-01, Decipher Prostate RP genomic risk assessment of trial participants demonstrated that patients with Decipher high-risk scores received greater benefit from hormonal therapy than those with Decipher low-risk scores. The study also validated Decipher Prostate RP as the most accurate predictor of metastasis, prostate cancer-specific survival, and overall survival in the context of a prospective, randomized controlled trial.
“Identifying which patients with recurrent disease are most likely to benefit from hormonal therapy will improve our ability to extend patient survival, while minimizing unnecessary toxicity for a large group of men with prostate cancer,” says
For more information, visit Decipher Biosciences.
1. Zhu J. Transcriptome profiling of NRG oncology/RTOG 9601: validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial [online summary of presentation by Feng FY, at the ASCO Genitourinary Cancer Symposium,
Featured image: Photo © Korrawin Khanta, courtesy Dreamstime (ID 125814902).